Yakkang Biotech (688046.SH) announced semi-annual results, with net profit of 111 million yuan to mother, an increase of 56.28% over the previous year

According to Zhitong Finance App News, Yakkang Biotech (688046.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 460 million yuan, an increase of 22.61% year on year; net profit attributable to shareholders of listed companies was 111 million yuan, up 56.28% year on year; after deducting non-net profit of 95.917,600 yuan, up 52.43% year on year; basic income per share was 0.27 yuan; the company plans to pay a cash dividend of 1.3 yuan (tax included) for every 10 shares.

During the reporting period, revenue increased by 22.61% over the same period last year, mainly due to strong demand from domestic industrial customers, accelerated expansion of overseas markets, and rapid growth in the functional efficacy business.

Total profit for the reporting period increased 60.47% over the previous period, net profit attributable to shareholders of listed companies increased 56.28% over the previous period, and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss increased 52.43% over the previous period. The main reason was that the company's operating income continued to grow and production capacity operation efficiency increased simultaneously; at the same time, management efficiency continued to be optimized, and the company's overall profitability gradually increased.